Jose Muratalla

Hepatocyte-Specific Loss of PPARγ Protects Mice From NASH and Increases the Therapeutic Effects of Rosiglitazone in the Liver

B. Layden, A. Diaz-Ruiz, G. Guzman, 2021, Cellular and molecular gastroenterology and hepatology.

Rosiglitazone requires hepatocyte PPARγ expression to promote steatosis in male mice with diet-induced obesity.

R. Kineman, C. Liew, P. Remón-Ruíz, 2021, Endocrinology.

Hepatocyte PPARγ contributes to the progression of non-alcoholic steatohepatitis in male and female obese mice

A. Diaz-Ruiz, B. Ramos-Molina, G. Guzman, 2022, bioRxiv.